Thomas Ciulla
CIK 1815426 · View on SEC EDGAR ↗
First SEC filing: Jan. 12, 2024 · Latest: Jan. 12, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 5, 2024 | VRDN | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 5, 2024 | VRDN | Stock Option (Right to Buy) | Common Stock (50,000) | $18.70 | Feb. 5, 2034 | 50,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 4 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Jan. 12, 2024 | VRDN | Common Stock | 762 | Direct |
| Jan. 12, 2024 | VRDN | Stock Option (Right to Buy)→ Common Stock (250,000) | 250,000 | Direct |
| Jan. 12, 2024 | VRDN | Stock Option (Right to Buy)→ Common Stock (50,000) | 50,000 | Direct |
| Jan. 12, 2024 | VRDN | Stock Option (Right to Buy)→ Common Stock (270,000) | 270,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
VRDN
Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $509,300 | $144,000 | — | — | $264,836 | — | $17,968 | $1,610,609 |
| 2023 | $414,037 | $235,088 | — | — | — | — | $1,806 | $10,646,112 |
| 2022 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.